— Know what they know.
Not Investment Advice

DERM NASDAQ

Journey Medical Corporation
1W: +7.7% 1M: -14.9% 3M: -8.4% YTD: -11.3% 1Y: -8.8% 3Y: +144.8%
$6.61
-0.11 (-1.64%)
 
Weekly Expected Move ±8.6%
$5 $6 $7 $7 $8
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 33 · $181.9M mcap · 15M float · 1.52% daily turnover · Short 39% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$181.9M
52W Range4.31-9.56
Volume125,128
Avg Volume226,270
Beta1.10
Dividend—
Analyst Ratings
3 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOClaude Maraoui
Employees58
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2021-11-12
9237 East Via de Ventura Boulevard
Scottsdale, AZ 85258
US
480 434 6670
About Journey Medical Corporation

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

Recent Insider Trades

NameTypeSharesPriceDate
Toledano Miranda Jay A-Award 50,000 — 2026-07-01
Smith Justin Adam A-Award 50,000 — 2026-07-01
Herskowitz Neil A-Award 50,000 — 2026-07-01
Toledano Miranda Jay A-Award 10,000 — 2026-06-25
ROSENWALD LINDSAY A A-Award 10,000 — 2026-06-25

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms